Prosecution Insights
Last updated: September 17, 2026
Application No. 18/259,844

METHOD FOR PREPARING ISOCYANATE COMPOUND

Final Rejection §103
Filed
Jun 29, 2023
Priority
Dec 30, 2020 — RE 10-2020-0187831 +1 more
Examiner
CARR, DEBORAH D
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hanwha Solutions Corporation
OA Round
2 (Final)
82%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
877 granted / 1072 resolved
+21.8% vs TC avg
Minimal +3% lift
Without
With
+2.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
51 currently pending
Career history
1110
Total Applications
across all art units

Statute-Specific Performance

§101
5.0%
-35.0% vs TC avg
§103
32.6%
-7.4% vs TC avg
§102
23.1%
-16.9% vs TC avg
§112
27.5%
-12.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1072 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments, see pages 6-9, filed 28 April 2026, with respect to the rejection of the claim under 35 USC§112 have been fully considered and are persuasive. The rejection of 1-2, 4, 9-15 has been withdrawn. Applicant's arguments filed 28 April 2026 regarding the rejection of claims 1-2, 4, 9-15 under 35 USC§103 have been fully considered but they are not persuasive. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 1-2, 4, 9-15 is/are rejected under 35 U.S.C. 103 as being unpatentable over KR 10-2019-0142642 (hereafter KR’642) in view of KR 10-2018-0127517 (hereafter KR’517) in further view of KR 10-2014-0136456 (hereafter KR’456). Applicant’s amendments to Claims 1 and 9 and corresponding arguments have been fully considered but are not persuasive for the reasons set forth below. Claim 1 Applicant has amended Claim 1 to recite specific operating conditions, including: compression of the gas phase to 16 bar or more, and distillation column top temperature of −15°C or more. Applicant further argues that these limitations distinguish the claimed process from the cited prior art. These arguments are not persuasive because the amended limitations merely recite optimization of known process variables. KR’642 and KR’517 both disclose integrated phosgene recovery systems involving gas-liquid separation, condensation, and distillation, and it would have been obvious to a person of ordinary skill in the art to optimize pressure and temperature conditions to achieve efficient condensation and separation of phosgene and hydrogen chloride. Gas compression pressure and column temperature are recognized result-effective variables in gas recovery and distillation systems. Selection of a pressure sufficient to achieve condensation of phosgene, and adjustment of column temperature to maintain efficient separation while minimizing energy consumption, represent routine process optimization well within the level of ordinary skill in the art. Accordingly, the recited ranges do not patentably distinguish over the combination of KR’642 and KR’517, as modified by KR’456, because the prior art teaches the same process steps and the claimed parameters represent routine optimization of known conditions. Claim 9 Applicant has amended Claim 9 to further define: removal of low boiling materials having a boiling point lower than that of the isocyanate compound, and removal of high boiling materials having a boiling point higher than that of the isocyanate compound. These amendments are not persuasive because KR’456 expressly teaches removal of low boilers and high boilers in the purification of isocyanate compounds, including separation of solvent, light ends, and heavy ends based on boiling point differences. The recitation of boiling point relative to the isocyanate product does not impart patentable distinction, as KR’456 already employs boiling point-based separation in substantially the same manner. Selection of specific classification criteria for low and high boiling fractions is an inherent and routine aspect of distillation design and does not alter the fundamental operation of the process. Therefore, Claim 9 remains unpatentable over KR’642 in view of KR’517 and KR’456. Conclusion The amendments to Claims 1 and 9 do not overcome the outstanding §103 rejection. The prior art continues to collectively disclose all claimed process steps, and the remaining differences relate only to routine optimization of known process parameters and conventional classification of distillation fractions. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEBORAH D CARR whose telephone number is (571)272-0637. The examiner can normally be reached Monday-Friday (10:30 am -6:30 pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 572-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DEBORAH D CARR/ Primary Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Jun 29, 2023
Application Filed
Feb 02, 2026
Non-Final Rejection mailed — §103
Apr 28, 2026
Response Filed
Jun 17, 2026
Final Rejection mailed — §103
Sep 03, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735384
METHODS FOR PREPARING (2S,3R,4R)-4,5-DIHYDROXYISOLEUCINE DERIVATIVE AND INTERMEDIATES THEREOF
1y 8m to grant Granted Sep 15, 2026
Patent 12709592
SALTS OF TREPROSTINIL
2y 4m to grant Granted Aug 18, 2026
Patent 12703678
IMPROVED PROCESS FOR PRODUCING 1, 5-PENTAMETHYLENE DIISOCYANATE FROM CADAVERINE SALT
3y 4m to grant Granted Aug 11, 2026
Patent 12697313
METHODS OF TREATING ANEMIA USING FORMOTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
1y 3m to grant Granted Aug 04, 2026
Patent 12692214
PROCESS OF MAKING ORGANIC COMPOUNDS
3y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
82%
Grant Probability
85%
With Interview (+2.8%)
2y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1072 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month